EP1438418A4 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus - Google Patents

Stem cells of the islets of langerhans and their use in treating diabetes mellitus

Info

Publication number
EP1438418A4
EP1438418A4 EP02768905A EP02768905A EP1438418A4 EP 1438418 A4 EP1438418 A4 EP 1438418A4 EP 02768905 A EP02768905 A EP 02768905A EP 02768905 A EP02768905 A EP 02768905A EP 1438418 A4 EP1438418 A4 EP 1438418A4
Authority
EP
European Patent Office
Prior art keywords
stem cells
cells
pancreatic
methods
islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02768905A
Other languages
German (de)
French (fr)
Other versions
EP1438418B1 (en
EP1438418A2 (en
Inventor
Joel F Habener
Henryk Zulewski
Melissa K Thomas
Elizabeth J Abraham
Mario Vallejo
Colin A Leech
Anna Louise Nolan
Andreas Lechner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/963,875 external-priority patent/US20020164307A1/en
Priority claimed from US10/136,891 external-priority patent/US6923959B2/en
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1438418A2 publication Critical patent/EP1438418A2/en
Publication of EP1438418A4 publication Critical patent/EP1438418A4/en
Application granted granted Critical
Publication of EP1438418B1 publication Critical patent/EP1438418B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
EP02768905A 2001-09-26 2002-09-26 Stem cells of the islets of langerhans and their use in treating diabetes mellitus Expired - Lifetime EP1438418B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US120687 1993-09-13
US963875 2001-09-26
US09/963,875 US20020164307A1 (en) 1999-12-06 2001-09-26 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US10/120,687 US20030082155A1 (en) 1999-12-06 2002-04-11 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US10/136,891 US6923959B2 (en) 1999-12-06 2002-05-02 Method of pre-inducing a state of immune tolerance before organ transplantation
US136891 2002-05-02
PCT/US2002/030700 WO2003026584A2 (en) 2001-09-26 2002-09-26 Stem cells of the islets of langerhans and their use in treating diabetes mellitus

Publications (3)

Publication Number Publication Date
EP1438418A2 EP1438418A2 (en) 2004-07-21
EP1438418A4 true EP1438418A4 (en) 2005-12-21
EP1438418B1 EP1438418B1 (en) 2010-11-24

Family

ID=38596629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02768905A Expired - Lifetime EP1438418B1 (en) 2001-09-26 2002-09-26 Stem cells of the islets of langerhans and their use in treating diabetes mellitus

Country Status (11)

Country Link
US (2) US20030082155A1 (en)
EP (1) EP1438418B1 (en)
JP (1) JP2005533746A (en)
CN (1) CN1589330A (en)
AT (1) ATE489475T1 (en)
AU (1) AU2002331910B2 (en)
CA (1) CA2461861A1 (en)
DE (1) DE60238431D1 (en)
HK (1) HK1067155A1 (en)
IL (1) IL161119A0 (en)
WO (1) WO2003026584A2 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4136434B2 (en) * 2002-04-17 2008-08-20 進 清野 Induction of insulin-producing cells
CA2493363A1 (en) * 2002-07-29 2004-02-05 Asahi Kasei Kabushiki Kaisha Stem cells for treating pancreatic damage
CA2567823A1 (en) * 2003-05-27 2004-12-09 Mcgill University In vitro platform for screening agents inducing islet cell neogenesis
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
ES2564044T3 (en) 2003-06-27 2016-03-17 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue and methods of preparing and using them
US7237119B2 (en) * 2003-06-30 2007-06-26 At&T Intellectual Property, Inc. Method, system and computer program for managing user authorization levels
CA2457296A1 (en) * 2003-08-19 2005-02-19 Takahiro Ochiya Methods for inducing differentiation of pluripotent cells
WO2005021728A2 (en) * 2003-08-27 2005-03-10 Stemcells California, Inc. Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2005071066A1 (en) * 2004-01-23 2005-08-04 Board Of Regents, The University Of Texas System Methods and compositions for preparing pancreatic insulin secreting cells
US8741635B2 (en) * 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
WO2006001471A1 (en) * 2004-06-29 2006-01-05 The University Of Tokyo Medicinal composition for promoting glucose-responsive insulin secretion
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
WO2006101548A2 (en) * 2004-12-21 2006-09-28 Ethicon, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US9056093B2 (en) 2005-01-07 2015-06-16 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
CN101188942B (en) * 2005-03-04 2011-11-30 生命扫描有限公司 Adult pancreatic derived stromal cells
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PL1888123T3 (en) * 2005-06-08 2013-06-28 Janssen Biotech Inc A cellular therapy for ocular degeneration
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
WO2007009356A1 (en) * 2005-07-15 2007-01-25 Theracells Biotechnologies Co., Ltd. A method for detecting and culturing pancreatic cells and their application
CN1982440B (en) * 2005-07-15 2010-11-17 广西南宁灵康赛诺科生物科技有限公司 Cultured pancreatic cell, its culturing method and use
WO2007027905A2 (en) * 2005-08-31 2007-03-08 Science And Technology Corporation @ Unm Human renal stem cells
PL1971681T3 (en) * 2005-12-16 2018-01-31 Depuy Synthes Products Inc Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007073552A1 (en) * 2005-12-19 2007-06-28 Ethicon, Inc. In vitro expansion of postpartum derived cells in roller bottles
ES2628129T3 (en) * 2005-12-28 2017-08-01 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using postpartum derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
CA2644922C (en) 2006-03-07 2019-07-23 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
CA2668223A1 (en) * 2006-10-31 2008-05-08 National Stem Cell Holding Inc. Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata
ES2507507T3 (en) * 2007-05-24 2014-10-15 Apceth Gmbh & Co. Kg Genetically modified CD34 negative mesenchymal stem cells for the treatment of tumors
WO2008153568A1 (en) * 2007-06-13 2008-12-18 Lifescan, Inc. Chorionic villus derived cells
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
EP2584034B8 (en) 2007-07-31 2017-12-06 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
KR101617243B1 (en) * 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 Differentiation of human embryonic stem cells
ES2525718T3 (en) * 2007-10-05 2014-12-29 DePuy Synthes Products, LLC Repair and regeneration of renal tissue by cells derived from human umbilical cord tissue
MX2010005805A (en) * 2007-11-27 2010-06-09 Lifescan Inc Differentiation of human embryonic stem cells.
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
JP5733986B2 (en) * 2008-02-21 2015-06-10 ヤンセン バイオテツク，インコーポレーテツド Methods, surface modified plates, and compositions for cell attachment, culture and detachment
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
KR101651661B1 (en) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 Differentiation of pluripotent stem cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
PL2346988T3 (en) * 2008-10-31 2017-10-31 Janssen Biotech Inc Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
US9012218B2 (en) * 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP5719305B2 (en) * 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド Methods and compositions for cell attachment and culture on a planar support
KR101774546B1 (en) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 Pluripotent stem cell culture on micro-carriers
JP5481841B2 (en) * 2008-11-28 2014-04-23 東ソー株式会社 Cytokeratin 19 mRNA measurement method
EP2379089B1 (en) * 2008-12-19 2019-04-17 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue following injury
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
AU2009327382B2 (en) * 2008-12-19 2014-07-17 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
GB0908934D0 (en) 2009-05-26 2009-07-01 Univ The West Of Scotland Differentiation medium
CN102482643B (en) 2009-07-20 2016-06-29 詹森生物科技公司 The differentiation of human embryo stem cell
EP2456858B1 (en) * 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2456859A4 (en) * 2009-07-20 2015-03-18 Janssen Biotech Inc Differentiation of human embryonic stem cells
CN102741395B (en) 2009-12-23 2016-03-16 詹森生物科技公司 The differentiation of human embryo stem cell
EP2516626B1 (en) * 2009-12-23 2017-05-10 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
JP6013196B2 (en) * 2010-03-01 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド Method for purifying cells derived from pluripotent stem cells
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2011296382B2 (en) 2010-08-31 2016-04-14 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2611907B1 (en) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CN102321572A (en) * 2011-01-29 2012-01-18 余跃红 Method for purifying and recognizing pancreatic endocrine cells
SG10201608914WA (en) 2011-12-22 2016-12-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
PL2794854T3 (en) 2011-12-23 2018-12-31 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
KR20140131999A (en) 2012-03-07 2014-11-14 얀센 바이오테크 인코포레이티드 Defined Media for Expansion and Maintenance of Pluripotent Stem Cells
US10066210B2 (en) 2012-06-08 2018-09-04 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
KR102058259B1 (en) 2012-06-26 2019-12-23 세라시스, 인코포레이티드 Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
JP6057574B2 (en) * 2012-07-11 2017-01-11 キヤノン株式会社 Hematopoietic stem cell identification probe
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
KR101942769B1 (en) 2012-12-31 2019-01-28 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
BR112015015714A2 (en) 2012-12-31 2017-07-11 Janssen Biotech Inc suspension and agglomeration of human pluripotent cells for differentiation into pancreatic endocrine cells
US10507220B2 (en) 2013-03-15 2019-12-17 Philadelphia Medical Scientific Center L.L.C. Cell therapy: a method and a composition for treating diabetes
CN117821369A (en) 2014-05-16 2024-04-05 詹森生物科技公司 Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
RU2579997C2 (en) * 2014-07-24 2016-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени Е.Д. Гольдберга" Сибирского отделения Российской академии медицинских наук Method of inducing targeted differentiation of multipotent progenitor cells of pancreas in insulin-producing beta cells during diabetes
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
AU2019345279B2 (en) * 2018-09-21 2022-10-27 APstem Therapeutics, Inc. Human pluripotent adult stem cells
MX2022011245A (en) 2020-03-11 2023-01-11 Bit Bio Ltd Method of generating hepatic cells.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010024824A1 (en) * 1999-12-06 2001-09-27 Moss Peter Ian Stem cells and their use in transplantation
WO2002012452A2 (en) * 2000-08-09 2002-02-14 Es Cell International Pte Ltd. Pancreatic progenitor cells
WO2003048336A2 (en) * 2001-12-04 2003-06-12 Organogenesis Inc. Cultured cells from pancreatic islets
WO2003054171A1 (en) * 2001-12-06 2003-07-03 The Regents Of The University Of California Method for differentiating islet precursor cells into beta cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514877A (en) 1995-10-25 1999-12-21 ユニバーシティ オブ フロリダ リサーチ ファウンデイション，インコーポレイテッド In vitro growth of functional islets of Langerhans and their use in vivo
US7622557B2 (en) * 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
AU776514B2 (en) * 1998-08-10 2004-09-09 General Hospital Corporation, The Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010024824A1 (en) * 1999-12-06 2001-09-27 Moss Peter Ian Stem cells and their use in transplantation
WO2002012452A2 (en) * 2000-08-09 2002-02-14 Es Cell International Pte Ltd. Pancreatic progenitor cells
WO2003048336A2 (en) * 2001-12-04 2003-06-12 Organogenesis Inc. Cultured cells from pancreatic islets
WO2003054171A1 (en) * 2001-12-06 2003-07-03 The Regents Of The University Of California Method for differentiating islet precursor cells into beta cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LECHNER A ET AL: "NESTIN-POSITIVE PROGENITOR CELLS DERIVED FROM ADULT HUMAN PANCREATIC ISLETS OF LANGERHANS CONTAIN SIDE POPULATION (SP) CELLS DEFINED BY EXPRESSION OF THE ABCG2 (BCRP1) ATP-BINDING CASSETTE TRANSPORTER", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 293, no. 2, 3 May 2002 (2002-05-03), pages 670 - 674, XP001097458, ISSN: 0006-291X *
MALIEPAARD MARC ET AL: "Subcellular localization and distribution of the Breast Cancer Resistance Protein transporter in normal human tissues", CANCER RESEARCH, vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 3458 - 3464, XP009056169, ISSN: 0008-5472 *
PECK A B ET AL: "PANCREATIC STEM CELLS: BUILDING, BLOCKS FOR A BETTER SURROGATE ISLET TO TREAT TYPE 1 DIABETES", ANNALS OF MEDICINE, FINNISH MEDICAL SOCIETY DUODECIM, HELSINKI, FI, vol. 33, no. 3, April 2001 (2001-04-01), pages 186 - 192, XP009006630, ISSN: 0785-3890 *
SORIA B: "In-vitro differentiation of pancreatic beta-cells", DIFFERENTIATION, SPRINGER VERLAG, DE, vol. 68, no. 4-5, October 2001 (2001-10-01), pages 205 - 219, XP002229903, ISSN: 0301-4681 *
ZULEWSKI H ET AL: "Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vino into pancreatic endocrine, exocrine and hepatic phenotypes", DIABETES, NEW YORK, NY, US, vol. 50, no. 3, March 2001 (2001-03-01), pages 521 - 533, XP002955659, ISSN: 0012-1797 *

Also Published As

Publication number Publication date
WO2003026584A3 (en) 2003-09-18
EP1438418B1 (en) 2010-11-24
WO2003026584A2 (en) 2003-04-03
ATE489475T1 (en) 2010-12-15
CN1589330A (en) 2005-03-02
AU2002331910B2 (en) 2007-10-11
JP2005533746A (en) 2005-11-10
US20030082155A1 (en) 2003-05-01
CA2461861A1 (en) 2003-04-03
DE60238431D1 (en) 2011-01-05
IL161119A0 (en) 2004-08-31
EP1438418A2 (en) 2004-07-21
HK1067155A1 (en) 2005-04-01
US8110399B2 (en) 2012-02-07
US20070128176A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
HK1067155A1 (en) Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1896571B1 (en) Materials and methods relating to cell based therapies
Mørch et al. Binding and leakage of barium in alginate microbeads
AU2007335753B2 (en) Scaffolding for tissue regeneration or repair
GB2393734A (en) Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
FI20085733A (en) Methods for treating disease using Sertoli cells and allografts or xenografts
AU3697900A (en) Pancreatic progenitor cells, methods and uses related thereto
WO2007081654A3 (en) Compositions and methods to enhance viability and function of islet cells
WO2003078588A3 (en) Primitive and proximal hepatic stem cells
WO2003048336A3 (en) Cultured cells from pancreatic islets
ATE553186T1 (en) DISC REPAIR AND METHOD THEREOF
PL1976544T3 (en) Method of using guava extract and composition including guava extract
Sambathkumar et al. Pluripotent stem cell-derived pancreatic progenitors and β-like cells for type 1 diabetes treatment
TR199903142T2 (en) CD154 blockade therapy for islet transplantation of pancreatic tissue.
Zhang et al. Evaluation of islets derived from human fetal pancreatic progenitor cells in diabetes treatment
Braaten et al. Removal of fibroblastoid cells from primary monolayer cultures of rat neonatal endocrine pancreas by sodium ethylmercurithiosalicylate
Kaczorowski et al. Glucose‐responsive insulin‐producing cells from stem cells
BRPI0316666B8 (en) new use of dextran sulfate
Roche et al. Role of small bioorganic molecules in stem cell differentiation to insulin-producing cells
WO2007015270A3 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
Hunag et al. Root canal sealers cause cytotoxicity and oxidative damage in hepatocytes
Tu et al. Comparison of fetal porcine aggregates of purified β-cells versus islet-like cell clusters as a treatment of diabetes
Hardikar et al. Stem-cell therapy for diabetes cure: how close are we?
JPWO2004099215A1 (en) Use of vinca alkaloids and their salts
Gasa et al. Regenerative Medicine for Diabetes Treatment: New β-Cell Sources

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040420

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067155

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051104

17Q First examination report despatched

Effective date: 20060118

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60238431

Country of ref document: DE

Date of ref document: 20110105

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101124

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1067155

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110224

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110307

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110825

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60238431

Country of ref document: DE

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170925

Year of fee payment: 16

Ref country code: GB

Payment date: 20170927

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170927

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60238431

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180926